Teknova to Participate in Upcoming Investor Conferences

Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products, including drug therapies, novel vaccines, and molecular diagnostics, today announced that the company will participate in the following upcoming investor conferences.

Piper Sandler 33rd Annual Healthcare Conference (Virtual)November 29 - December 2, 2021Teknova’s pre-recorded presentation with President and Chief Executive Officer, Stephen Gunstream, will be available online at the conference website at 10:00 a.m. ET on Monday, November 22, 2021.

Stephens 23rd Annual Investment Conference (Nashville, TN)December 1 - 3, 2021Gunstream and Matt Lowell, Teknova’s Chief Financial Officer, will be participating in a fireside chat at 8:00 a.m. CT/9:00 a.m. ET on Friday, December 3, 2021.

The presentations will be webcast and may be accessed from the Investor Relations section of the Company’s website: https://ir.teknova.com/. The webcasts will be available on the Company’s website for approximately 90 days after each event.

About TeknovaTeknova is expediting clinical breakthroughs in the life sciences by providing custom products and reagents for bioprocessing, bioproduction, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high quality, custom, made-to-order products on short turnaround times and at scale across all stages of development, including commercialization. For more information about Teknova, visit www.teknova.com.

Investor ContactsMatt LowellChief Financial [e-mail][phone]

Sara MichelmoreMacDougall [e-mail][phone]

Media ContactMatthew CorcoranMacDougall [e-mail][phone]